subslover
5年前
INmune Bio, Inc. Announces Interim Phase Ib Data Demonstrating That XPro1595 Decreases Neuroinflammation in Patients with Alzheimer’s Disease
XPro1595 reduces neuroinflammation by 40.6% in a brain fiber pathway important for learning and memory
LA JOLLA, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today reported clinical data demonstrating that its lead drug candidate, XPro1595, decreases neuroinflammation in patients with Alzheimer’s disease. Interim results from a Phase Ib clinical trial show that treatment with XPro1595 decreases white matter free water, a biomarker of neuroinflammation measured by MRI. XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that selectively neutralizes soluble TNF, an inflammatory cytokine implicated in Alzheimer's pathology, without affecting transmembrane TNF or the TNF receptors.
Specifically, INmune compared biomarker data obtained from six patients treated with XPro1595 for 12 weeks with data from 25 Alzheimer’s patients from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) that are part of a natural history database in patients with Alzheimer’s. Over a 12-week period, whole brain inflammation increased by 5.1% in the ADNI patients compared to an increase of 1.7% and a decrease of 2.3% in patients treated weekly with 0.3mg/kg or 1.0mg/kg of XPro1595, respectively. A more detailed analysis revealed a 40.6% reduction in neuroinflammation in the Arcuate Fasciculus in patients treated with XPro1595. The Arcuate Fasciculus is a major white matter anterior/posterior tract (white matter bundle) containing long and short fibers that connects the frontal, parietal and temporal lobes and is important for language and short-term memory. By contrast, the ADNI cohort had a 4.6% increase in Arcuate Fasciculus neuroinflammation.
“We are extremely encouraged by these findings at such an early stage in our clinical trial,” said CJ Barnum, Ph.D., Director of Neuroscience at INmune. “Not only do we see a clear reduction in neuroinflammation, but we also know where in the brain this is occurring, which may inform us on the domains of cognition that might be affected.”
According to Sharon Cohen, M.D., FRCPC, a neurologist and Medical Director of Toronto Memory Program who is not involved with the clinical trial: “The preliminary results from INmune Bio’s Phase Ib study add to the growing enthusiasm for tackling neuroinflammation in the treatment of Alzheimer’s disease. Furthermore, MRI assessment of free water content in the brain holds promise as an exciting surrogate marker for tracking the impact of such treatment.”
INmune will host a key opinion leader (KOL) event at 8 a.m. EDT tomorrow. A brief presentation of the data by the company will be followed by a panel discussion and Q&A with:
Dr. Rosalyn Lai, a psychiatrist and Principal Investigator at KaRa MINDS in Sydney, Australia, that is enrolling patients in the Phase Ib Alzheimer’s study.
Max Descoteaux, Ph.D., Professor, Computer Science Department, Sherbrooke University, CSO of Imeka and an expert in imaging brain connectivity, from state-of-the-art diffusion MRI acquisition, reconstruction, tractography, processing and visualization.
Judith Jaeger Ph.D., President and Principal Scientist of CognitionMetrics, LLC, an internationally recognized cognitive neuropsychologist.
Malu Tansey, Ph.D., a professor of Neuroscience and Neurology at the Medical College of the University of Florida, and an internationally recognized expert in neuroinflammation and Alzheimer’s disease.
KOL Event Information
To participate in this event you must register in advance. After registering, you will receive a confirmation email containing information about joining the webinar.
To register and access the live webinar click here
Date: July 14, 2020
Time: 8:00 AM Eastern Time
About XPro1595
XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that acts differently than currently existing TNF inhibitors in that it neutralizes soluble TNF (sTNF) without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro1595 could have beneficial effects in patients with Alzheimer’s disease by decreasing neuroinflammation. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit this section of the INmune Bio’s website.
About XPro1595 Clinical Trial
XPro1595 is currently being evaluated in Phase Ib clinical trial in Alzheimer’s disease patients who have biomarkers of inflammation to determine if neutralizing soluble TNF can decrease those biomarkers of neuroinflammation. There cannot be any assurance about the results of this trial.
Adults (>18 years old) diagnosed with probable Alzheimer’s disease defined by the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria, confirmed with inflammatory biomarkers, are being enrolled in this multicenter, Phase Ib open-label study. The study will follow patients during a 12-week period to determine the safety and the ability of XPro1595 to reduce neuroinflammation using a combination of biomarkers of inflammation. The study will examine inflammatory and disease-related biomarkers before treatment, at the halfway point, and at the end. Cognitive and neuropsychiatric symptoms will be also be measured during the trial. The study will identify the dose of XPro1595 to be used in a larger Phase II disease modification study.
Clinical sites are located in Australia and include KaRa MINDS in New South Wales, Central Adelaide Local Health Network in South Australia, Austin Health and Alfred Health in Victoria, and The Australian Alzheimer's Research Foundation in Western Australia.
For additional clinical trial details, please refer to https://clinicaltrials.gov/ct2/show/NCT03943264?term=Xpro1595&rank=1
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, LIVNate, Quellor™ and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contact:
David Moss, CFO (858) 964-3720
DMoss@INmuneBio.com
Investor Contact:
James Carbonara (646) 755-7412
James@haydenir.com
Source: INmune Bio, Inc.
© 2020 GlobeNewswire, Inc.
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
Nasdaq
DAILY ADVANCERS
LVCLY
+ 87.50 %
BBXTB
+ 30.00 %
WEYL
+
TFMG
6年前
INMB is our fresh Nasdaq Stock Alert set for huge reversal trade
=====================
INmune Bio Inc. (INMB)
Alert Price: $8.82
Float: 2.82M
Corporate Presentation
Fact Sheet
12-Month Consensus Price Target: $13.00 (Maxim Group)
Website | Recent News
========================
Members,
July was one of our most profitable months of 2019.
We delivered 6 solid winners in a row for a grand total of +270% in realistic gains!
We now plan to kickoff the month of August with what could be one of our biggest long-term winners yet.
Just like two of our most recent winners, the Company trades on the NASDAQ exchange and has tremendous growth potential.
Please turn your immediate attention to INmune Bio Inc. (INMB).
INMB is a clinical stage biotechnology company that is developing new immunotherapies that reprogram a patient’s innate immune system to allow the immune system to fight cancer and Alzheimer’s.
INmune Bio Inc. is a developing novel therapies targeting distinct parts of a patient’s innate immune system to fight disease. Drug candidates, INKmune™ and INB03, may be used to treat cancer. XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease. INmune Bio’s product platforms utilize a precision therapy approach, promoting the body’s innate immune response to treat unsolved problems in medicine.
INMB's therapies provide treatment for diseases that effect millions of patients each year.
Alzheimer’s Disease – The Alzheimer’s disease therapeutics market will grow to be worth more than $12 billion annually by 2026.
Cancer Residual Disease – About 1.7 million patients are affected by this every year, with nearly 610,000 patients dying as a result.
Checkpoint Inhibitor Market – The global checkpoint inhibitor market will grow to be worth more than $40 billion annually by the year 2026.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer ( NK ) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid-derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit http://www.inmunebio.com.
INMB Pipeline
INKmune-Cancer - in oncology patients that relapse, cells that are known to target residual cancer cells, fail to eliminate the remainder of the disease after treatment. INMB is working to keep this from happening with INKmune.
INB03-Alzheimers - targets myeloid derived suppressor cells, or MDSC, believed to be the reason that many cancer patients do not respond to checkpoint inhibitor treatments.
XPro1595-Cancer – is under development as a potential option for patients with Alzheimer’s disease, believed to be caused by neuroinflammation of brain cells. The company believes XPro1595 will inhibit neuroinflammation and the resultant cell death.
INMB's Pipeline's Multi-Billion Dollar Market Opportunity
• XPro1595 - Alzheimer’s/dementia market*
– 5.8 M patients in US
– 2019 est cost to care for US AD patients $280B
• INKmune
- Cancer residual disease market **
– 1,735,350 new cases and 609,640 people will die
– Initial targets: Ovarian Cancer and High Risk MDS
• INB03
- Resistance to Checkpoint Inhibitors market***
– CPI’s work 27% of patients. CPI 2025 est market size $56B
– INB03 in combination with CPI’s should increase the number of patients sensitive to CPIs. – Initial targets: Melanoma and Renal Cell Cancer
All three of the candidates in the company’s pipeline are either currently in Phase 1 clinical studies or are about to begin Phase 1 clinical studies in the near term.
INB03 Australia Solid Tumors Initial Phase 1 Data Readout- Q3 ’19
INKmune UK Ovarian Cancer Initiate Enrollment of Phase 1/2 study - Q4 ’19
INB03 Australia Solid Tumors Initiate Combination Study, Additional Cohorts to Phase 1 Study- 1H ’20
XPro1595 UK Alzheimer’s Initiate Enrollment of Phase 1 Study - Q3’19
INKmune UK Ovarian Cancer Report Initial Phase 1 Data - 1H ’20
XPro1595 UK Alzheimer’s Early Data - Q1’20
INKmune UK Ovarian Cancer Initiate Phase 2 Study - 2H ’20
INB03 Australia/US Solid Tumors Initiate INB03 + CPI* Phase 2 Combination Study - 1H ’20
The Alzheimer Association believes in IMNB
In order to advance XPro1595 in the treatment of AD, INmune was recently awarded a $1 million grant from the Alzheimer’s Association.
The grant will support a biomarker-directed Phase 1 clinical trial in 18 patients with mild-to-moderate AD. XPro1595 will be administered subcutaneously once a week for three months and biomarkers of inflammation will be assessed at 0, 6, and 12 weeks.
This ringing endorsement from the Alzheimer Association should have potential investors sold on IMNB's potential to help treat this dreaded disease that effects 5.8M patients in the U.S. alone.
The Smart Money Is Buying Up Shares In IMNB
Insiders own 63% of the outstanding shares of INMB.
Insiders have spent $770,000 buying up company shares in the past two months.
The Company has zero debt!
The fact that insiders own 63% of the shares, has us bullish on INMB's growth potential.
Who would know better if the Company was undervalued than those working within.
Tiny Float = Big Move Potential
The public float for IMNB is just 2.98M
A float that low is a rarity for companies listed on the NASDAQ.
It also means the IMNB could moonshot if it were to see an increase in daily volume .
In fact, the first time IMNB broke over 100K in daily volume , its shares had their biggest single day move, climbing from $8.80 to $10.68, for a single day gain of over +21%!
INMB Trades Under $9 And Has A $13 Price Target
In March, Maxim Group launched coverage of INMB with a “buy” rating and $13 price target.
Analyst Jason McCarthy stated that INB03, a selective TNF inhibitor downregulates the immunosuppressive factors found in the tumor microenvironment, turning cold tumors hot. An open-label Phase 1 study is ongoing, with data expected in the second quarter of 2019.
He said XPro1595 selectively targets the soluble form of TNF and may inhibit activated microglia, a type of innate immune cell, representing a differentiated approach, compared with targeting beta amyloid or tau.
XPro1595’s preclinical data has been positive, he said, and a Phase 1 study is scheduled to start in the second quarter of 2019. Also initiating in the second quarter of 2019 is a Phase 1/2 study of INKmune, a modified tumor cell line that primes existing natural killer cells.
“Innate immunity is a space that continues to evolve and rise behind CAR-T and checkpoints (both target adaptive immunity), with multiple players in the space, including big pharma/biotech,” Mr. McCarthy said. “INmune's programs should report data in 2019 providing catalysts for the stock to support a higher valuation,” he added.
With an upside of over +47%, now could be the perfect time to start building a position in INMB.
Recent Developments
INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit
This week, RJ Tesi, M.D., co-founder and CEO , will present at the Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit.
We will be keeping a close eye on this, as any data that comes out could serve as a strong bullish catalyst for INMB's share price.
Technical Analysis
We've done our very own chart analysis on INMB, and we the potential for a move of over 21%!
The stock has seen multiple bounces and reversals from these levels, which leads us to believe that now may be the perfect entry point for those looking to capitalize on INMB's next potential chart reversal.
The Bottom-Line
We don't think INMB will be trading under the radar for much longer.
Any positive data released by the Company could grab the attention of Wall St .
With its low-float, INMB could see a huge run-up.
ZERO Debt and Heavy Insider Ownership have us bullish heading into the 2nd half of 2019.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by World Wide Holdings dba Invictus Resources for a 1-day investor relations advertising marketing campaign w/ 1500 TradingView™ views for INMB. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
TFMG
6年前
INMB is our fresh Nasdaq Stock Alert set for huge reversal trade
=====================
INmune Bio Inc. (INMB)
Alert Price: $8.82
Float: 2.82M
Corporate Presentation
Fact Sheet
12-Month Consensus Price Target: $13.00 (Maxim Group)
Website | Recent News
========================
Members,
July was one of our most profitable months of 2019.
We delivered 6 solid winners in a row for a grand total of +270% in realistic gains!
We now plan to kickoff the month of August with what could be one of our biggest long-term winners yet.
Just like two of our most recent winners, the Company trades on the NASDAQ exchange and has tremendous growth potential.
Please turn your immediate attention to INmune Bio Inc. (INMB).
INMB is a clinical stage biotechnology company that is developing new immunotherapies that reprogram a patient’s innate immune system to allow the immune system to fight cancer and Alzheimer’s.
INmune Bio Inc. is a developing novel therapies targeting distinct parts of a patient’s innate immune system to fight disease. Drug candidates, INKmune™ and INB03, may be used to treat cancer. XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease. INmune Bio’s product platforms utilize a precision therapy approach, promoting the body’s innate immune response to treat unsolved problems in medicine.
INMB's therapies provide treatment for diseases that effect millions of patients each year.
Alzheimer’s Disease – The Alzheimer’s disease therapeutics market will grow to be worth more than $12 billion annually by 2026.
Cancer Residual Disease – About 1.7 million patients are affected by this every year, with nearly 610,000 patients dying as a result.
Checkpoint Inhibitor Market – The global checkpoint inhibitor market will grow to be worth more than $40 billion annually by the year 2026.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer ( NK ) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid-derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit http://www.inmunebio.com.
INMB Pipeline
INKmune-Cancer - in oncology patients that relapse, cells that are known to target residual cancer cells, fail to eliminate the remainder of the disease after treatment. INMB is working to keep this from happening with INKmune.
INB03-Alzheimers - targets myeloid derived suppressor cells, or MDSC, believed to be the reason that many cancer patients do not respond to checkpoint inhibitor treatments.
XPro1595-Cancer – is under development as a potential option for patients with Alzheimer’s disease, believed to be caused by neuroinflammation of brain cells. The company believes XPro1595 will inhibit neuroinflammation and the resultant cell death.
INMB's Pipeline's Multi-Billion Dollar Market Opportunity
• XPro1595 - Alzheimer’s/dementia market*
– 5.8 M patients in US
– 2019 est cost to care for US AD patients $280B
• INKmune
- Cancer residual disease market **
– 1,735,350 new cases and 609,640 people will die
– Initial targets: Ovarian Cancer and High Risk MDS
• INB03
- Resistance to Checkpoint Inhibitors market***
– CPI’s work 27% of patients. CPI 2025 est market size $56B
– INB03 in combination with CPI’s should increase the number of patients sensitive to CPIs. – Initial targets: Melanoma and Renal Cell Cancer
All three of the candidates in the company’s pipeline are either currently in Phase 1 clinical studies or are about to begin Phase 1 clinical studies in the near term.
INB03 Australia Solid Tumors Initial Phase 1 Data Readout- Q3 ’19
INKmune UK Ovarian Cancer Initiate Enrollment of Phase 1/2 study - Q4 ’19
INB03 Australia Solid Tumors Initiate Combination Study, Additional Cohorts to Phase 1 Study- 1H ’20
XPro1595 UK Alzheimer’s Initiate Enrollment of Phase 1 Study - Q3’19
INKmune UK Ovarian Cancer Report Initial Phase 1 Data - 1H ’20
XPro1595 UK Alzheimer’s Early Data - Q1’20
INKmune UK Ovarian Cancer Initiate Phase 2 Study - 2H ’20
INB03 Australia/US Solid Tumors Initiate INB03 + CPI* Phase 2 Combination Study - 1H ’20
The Alzheimer Association believes in IMNB
In order to advance XPro1595 in the treatment of AD, INmune was recently awarded a $1 million grant from the Alzheimer’s Association.
The grant will support a biomarker-directed Phase 1 clinical trial in 18 patients with mild-to-moderate AD. XPro1595 will be administered subcutaneously once a week for three months and biomarkers of inflammation will be assessed at 0, 6, and 12 weeks.
This ringing endorsement from the Alzheimer Association should have potential investors sold on IMNB's potential to help treat this dreaded disease that effects 5.8M patients in the U.S. alone.
The Smart Money Is Buying Up Shares In IMNB
Insiders own 63% of the outstanding shares of INMB.
Insiders have spent $770,000 buying up company shares in the past two months.
The Company has zero debt!
The fact that insiders own 63% of the shares, has us bullish on INMB's growth potential.
Who would know better if the Company was undervalued than those working within.
Tiny Float = Big Move Potential
The public float for IMNB is just 2.98M
A float that low is a rarity for companies listed on the NASDAQ.
It also means the IMNB could moonshot if it were to see an increase in daily volume .
In fact, the first time IMNB broke over 100K in daily volume , its shares had their biggest single day move, climbing from $8.80 to $10.68, for a single day gain of over +21%!
INMB Trades Under $9 And Has A $13 Price Target
In March, Maxim Group launched coverage of INMB with a “buy” rating and $13 price target.
Analyst Jason McCarthy stated that INB03, a selective TNF inhibitor downregulates the immunosuppressive factors found in the tumor microenvironment, turning cold tumors hot. An open-label Phase 1 study is ongoing, with data expected in the second quarter of 2019.
He said XPro1595 selectively targets the soluble form of TNF and may inhibit activated microglia, a type of innate immune cell, representing a differentiated approach, compared with targeting beta amyloid or tau.
XPro1595’s preclinical data has been positive, he said, and a Phase 1 study is scheduled to start in the second quarter of 2019. Also initiating in the second quarter of 2019 is a Phase 1/2 study of INKmune, a modified tumor cell line that primes existing natural killer cells.
“Innate immunity is a space that continues to evolve and rise behind CAR-T and checkpoints (both target adaptive immunity), with multiple players in the space, including big pharma/biotech,” Mr. McCarthy said. “INmune's programs should report data in 2019 providing catalysts for the stock to support a higher valuation,” he added.
With an upside of over +47%, now could be the perfect time to start building a position in INMB.
Recent Developments
INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit
This week, RJ Tesi, M.D., co-founder and CEO , will present at the Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit.
We will be keeping a close eye on this, as any data that comes out could serve as a strong bullish catalyst for INMB's share price.
Technical Analysis
We've done our very own chart analysis on INMB, and we the potential for a move of over 21%!
The stock has seen multiple bounces and reversals from these levels, which leads us to believe that now may be the perfect entry point for those looking to capitalize on INMB's next potential chart reversal.
The Bottom-Line
We don't think INMB will be trading under the radar for much longer.
Any positive data released by the Company could grab the attention of Wall St .
With its low-float, INMB could see a huge run-up.
ZERO Debt and Heavy Insider Ownership have us bullish heading into the 2nd half of 2019.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by World Wide Holdings dba Invictus Resources for a 1-day investor relations advertising marketing campaign w/ 1500 TradingView™ views for INMB. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Hot Features
プレミアム
登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
MartinLutherKing
2月前
Monksdream
2月前
tw0122
4月前
jondoeuk
11月前
DollarDan
1年前
conix
3年前
spartex
4年前
Fress
4年前
l2 hunter
5年前
starkd748
5年前
ClayTrader
5年前
$treet $inatra
5年前
biigboy7
5年前
MasterBlastr
6年前
reverse_long
6年前
